bpc-157 vs larazotide

bpc-157 (A-tier) vs larazotide (D-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

bpc-157 · tier A

the contested repair peptide. strong animal data, thin human trials, huge community gravity.

the contested repair peptide. 200+ rat studies with consistent tissue-repair signals. zero published controlled human RCTs in tendon or injury recovery.

200+ rodent · 0 RCTs · half-life short (minutes IV) · healing

larazotide · tier D

larazotide acetate (AT-1001) is an eight-amino-acid oral tight-junction regulator. a celiac phase 2b found a symptom benefit at 0.5 mg three times daily, but the pivotal phase 3 was terminated after an interim sample-size review and posted no results.

the phase 2b symptom signal did not become pivotal confirmation: the celiac phase 3 was terminated without posted results. the molecule remains in a separate Long COVID study, also without posted results, and has no US approval.

342 adults in the published celiac phase 2b · half-life systemic half-life not established; company assays did not detect larazotide or peptide metabolites in human serum · healing

at a glance

• bpc-157: tier A · 200+ rodent · 0 RCTs
• larazotide: tier D · 342 adults in the published celiac phase 2b

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.